These are the SUSTAIN and STEP trials
About 15% of participants in a recent study reported experiencing severe withdrawal symptoms, which include dizziness, headaches, nausea, and insomnia, according to Moshfeghinia R et al
However, this scenario is increasingly uncommon because modern GLP-1/GIP agonists like tirzepatide achieve weight loss that historically required combination therapy
The ERK signaling pathway is crucial for protein translational regulation, particularly in the context of long-term potentiation, which is essential for synaptic plasticity and memory formation
The FDA-approved BMI thresholds are the same for both medications: 30 or higher, or 27 or higher with at least one weight-related comorbidity
, but many members on this forum use Sub-cut successfully